Hyperlipoproteinemias:
Indications for LOFIBRA TABLETS:
Adjunct to diet in hypertriglyceridemia (Types IV and V), and to reduce elevated total-C, LDL-C, apo B, and TG, and to increase HDL-C, in primary hypercholesterolemia and mixed dyslipidemia (Types IIa and IIb).
Adult:
Take with food. Hypertriglyceridemia: 54mg–160mg/day; adjust in 4–8 week intervals. Hypercholesterolemia, dyslipidemia: 160mg/day. Renal impairment (CrCl<50mL/min): initially 54mg/day. Discontinue if inadequate response after 2 months on max dose.
Children:
Not recommended.
Contraindications:
Hepatic dysfunction. Primary biliary cirrhosis. Severe renal dysfunction. Gallbladder disease.
Warnings/Precautions:
Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Also:
Pharmacologic Class:
Fibrate.
Interactions:
Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.
Adverse Reactions:
Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.
How Supplied:
Tabs—90
Caps—100
